Table 3.
Comparison of indicators in the use of rhTPO for treatment of grade II, III, and IV thrombocytopenia [n, (%)].
| Indicators | Use of recombinant human thrombopoietin (rhTPO) | χ 2 value | P Value | ||
|---|---|---|---|---|---|
| Grade II (n = 100) | Grade III (n = 94) | Grade IV (n = 39) | |||
| Delay of the next chemoradiotherapy/radiotherapy cycle due to platelet decline | |||||
| No | 56 (56.0) | 40 (42.6) | 14 (35.9) | 5.921 | 0.052 |
| Yes | 44 (44.0) | 54 (57.4) | 25 (64.1) | ||
| Regimen change due to altered platelet count | |||||
| No | 85 (85.0) | 88 (93.6) | 32 (82.1) | 4.962 | 0.084 |
| Yes | 15 (15.0) | 6 (6.4) | 7 (17.9) | ||
| Dose reduction of chemoradiotherapy due to platelet decline | |||||
| No | 85 (85.0) | 81 (86.2) | 31 (79.5) | 0.970 | 0.616 |
| Yes | 15 (15.0) | 13 (13.8) | 8 (20.5) | ||
| Days of treatment | 5.00 (3.00, 6.00) | 6.00 (4.00, 8.00) | 6.00 (4.00, 11.00) | 16.319 | <0.001 |
| Time to increase platelets (days) | 3.00 (2.00, 5.00) | 5.50 (3.00, 8.00) | 6.00 (3.00, 11.00) | 31.828 | <0.001 |
| Delay of the next chemoradiotherapy cycle (days) | 0 (0, 5.75)> | 3.00 (0, 9.25) | 3.00 (0, 8.00) | 8.460 | 0.015 |
| Prolonged hospitalization due to platelet decline (days) | 1.00 (0, 6.00) | 3.50 (0, 7.00) | 5.00 (0, 8.00) | 7.908 | 0.019 |
| Increased hospitalization costs due to platelet decline | 5040.00 (3024.00, 6979.00) | 6503.00 (5040.00, 9474.00) | 7440.00 (5874.00, 14410.00) | 35.347 | <0.001 |
| Platelet transfusion | |||||
| No | 95 (95.0) | 67 (71.3) | 16 (41.0) | 47.616 | <0.001 |
| Yes | 5 (5.0) | 27 (28.7) | 23 (59.0) | ||